Innovative Industrial Properties, Inc.

Innovative Industrial Properties, Inc. (NYSE: IIPR) owns specialized properties leased mainly to regulated cannabis operators. It also earns interest and dividends from investments in life-science property company IQHQ and its affiliates.

Third-quarter financial results

The table compares the three months ended September 30. Amounts are USD millions, except per-share figures. Net income is attributable to common stockholders.

AFFO starts with common-stockholder net income, adds back real estate depreciation and impairment, and adjusts for litigation, stock compensation, financing and other specified items. The measure uses a company-defined diluted share count that excludes potential shares from conversion of its exchangeable notes.

Q2 2026 AFFO was $53.0 million, or $1.83 per share. In Q3 it rose to $54.8 million, or $1.96. Weighted shares used for AFFO fell to 27.962 million from 28.972 million. The declared common dividend remained $1.90.

During Q2, IIPR repurchased approximately 1.47 million shares for $89 million. It also issued 680,842 common shares for $34.8 million after fees. Most of the repurchases accompanied its $402.5 million issue of 6.0% exchangeable notes due June 2029.

Tenant collections and leasing

Q3 revenue included $3.8 million of previously collected security deposits applied to rent, compared with $0.8 million a year earlier. Operating income was $29.4 million, essentially unchanged from the prior-year quarter.

The company's leased-portfolio measure fell to 90.0% at September 30 from 95.8% in June. It weights properties by invested capital, excludes redevelopment and includes leases in default. IIPR terminated 16 leases and entered into six new leases in Q3.

All PharmaCann leases had been terminated by September 30. A former 4Front property in Washington was re-leased in August; arrangements for three other 4Front properties remain tied to licensing and receivership proceedings, expected to conclude in late 2026 or early 2027.

An October lease for the Saxton, Pennsylvania property remains subject to cannabis-license transfer approval.

Life-science investments and earlier expectations

When IIPR announced its original $270 million IQHQ commitment in 2025, it expected funding to run through Q2 2027. The investment was fully funded by June 2026. An additional $30 million in preferred equity in September brought the strategic investment to $300 million, comprising a $100 million credit facility and $200 million in preferred equity.

Separately, on September 28, IIPR closed a $245 million mezzanine loan commitment for Alewife Park in Cambridge, Massachusetts. It funded approximately $111 million initially, mainly to repay an $85 million bridge loan plus interest, fees and related amounts. The remaining $134 million is expected to be funded through Q4 2027, subject to draw conditions.

This is a loan secured by ownership interests in the property-owning entities. It matures in February 2028 with a conditional one-year extension. IIPR expects an average interest yield of approximately 15.8% over the loan's term.

IQHQ investments contributed $10.4 million of interest and dividend income in Q3. Our comparison of nine-month and first-half cash statements identifies about $2.5 million of paid-in-kind life-science income during Q3.

Cash flow and funding

Operating cash flow was $49.5 million in Q3, derived from $150.4 million over nine months less $100.9 million in the first half. Common dividends paid during Q3 were $53.1 million, reflecting the Q2 declaration paid July 15. The Q3 dividend was paid October 15.

At September 30, cash and equivalents were $142.4 million and gross debt principal was $711.6 million. In October, IIPR received repayment of its $49 million Perth property seller-financing loan.

After quarter-end, IIPR completed a $54.2 million gross preferred-stock offering carrying a 9.25% rate. It also extended its $87.5 million revolving credit facility for 90 days, to January 21, 2027.